News

On March 2, 2015, MédiS obtained authorization to market the first human-origin recombinant alpha erythropoietin (EPO), marking a significant milestone in the Tunisian pharmaceutical industry.

MediS, dedicated to serving health, embodies our laboratory's philosophy. Over the years, we have consistently provided patients with high-quality medications while ensuring cost-effectiveness in managing their conditions, particularly pain.